Repare Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025. The company recorded $0 in revenue from collaboration agreements, a significant decrease from $52.404 million in Q1 2024. The net loss for the quarter was $(30.043) million, compared to a net income of $13.162 million in the prior year period.
Research and development expenses decreased to $20.270 million in Q1 2025 from $32.970 million in Q1 2024, reflecting ongoing cost-saving measures. General and administrative expenses also saw a reduction to $7.652 million from $8.618 million. Restructuring expenses for the quarter amounted to $3.265 million.
As of March 31, 2025, Repare held $124.2 million in cash, cash equivalents, and marketable securities. The company remains on track to report initial data for both the LIONS and POLAR trials in the second half of 2025 and recently out-licensed its discovery platforms to DCx Biotherapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.